I n this study, Clair et al. use a systematic review and metaanalysis to describe and quantify the association between s m o k i n g a n d a m i c r o v a s c u l a r c o m p l i c a t i o n o f diabetes-diabetic peripheral neuropathy (DPN). The odds of being a smoker were higher in patients who developed DPN.
1 This was observed in prospective studies that adjusted for covariates (HbA1c etc.), that studied type 1 patients (n=3854), and that had a follow-up period of≥5 years. It was not seen among type 2 diabetics (n=1317 patients) and with a follow-up period<5 years.
Smoking has been identified as a risk factor for progression of microvascular complications in type 1 and nephropathy in type 2 diabetes. 2, 3 It is thought to be a risk factor for development of type 2 diabetes mellitus (DM). 4 The relationship between smoking and other microvascular complications (retinopathy, neuropathy) in type 2 DM is unclear. In fact, one of the largest prospective studies (n=903 patients) concluded that smoking might offer Bprotectionâ gainst development and progression of retinopathy. 5 A similar signal of Bprotection^could be inferred from this study's analyses of type 2 DM patients, although it could also be argued that the analysis was underpowered.
Prospective studies that are suitably powered are needed in type 2 diabetes patients. If this signal of Bprotection^is replicated, it certainly opens up avenues for investigating novel compounds for treating a costly complication. It also raises the question, BDoes the natural history of microvascular complications differ between patients with type 1 and type 2 diabetes?^. The association seen in type 1 patients, combined with its propensity to worsen insulin resistance in type 2 patients, should serve as some among the many reasons to encourage tobacco cessation in our diabetic patients. Further studies are needed to define risk factors and to understand the epidemiology of this debilitating condition. This study adds to the wealth of evidence suggesting smoking as a risk factor for the development of DPN in patients with type 1 diabetes and raises important questions about DPN in type 2 patients.
